IMUX Immunic Inc

Price (delayed)

$14.41

Market cap

$196.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.08

Enterprise value

$9.8M

?
Relative Growth: Rel. Growth: 16
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's ...

Highlights
The EPS has increased by 47% YoY and by 18% from the previous quarter
The company's debt rose by 36% QoQ but it fell by 30% YoY
Immunic's net income has decreased by 8% YoY and by 7% QoQ

Key stats

What are the main financial stats of IMUX

IMUX stock price

How has the Immunic stock price performed over time
Intraday
1.69%
1 week
-3.74%
1 month
35.69%
1 year
85.94%
YTD
169.85%
QTD
29.82%

Financial performance

How have Immunic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$109.64M
Net income
-$104.29M
Gross margin
N/A
Net margin
N/A
IMUX's operating income is down by 9% year-on-year and by 6% since the previous quarter
Immunic's net income has decreased by 8% YoY and by 7% QoQ

Price vs fundamentals

How does IMUX's price correlate with its fundamentals

Growth

What is Immunic's growth rate over time

Valuation

What is Immunic stock price valuation
P/E
N/A
P/B
1.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 47% YoY and by 18% from the previous quarter
The price to book (P/B) is 45% lower than the 5-year quarterly average of 2.2

Efficiency

How efficient is Immunic business performance
The company's return on equity has surged by 82% QoQ and by 32% YoY
The company's return on assets has surged by 50% QoQ and by 27% YoY

Dividends

What is IMUX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMUX.

Financial health

How did Immunic financials performed over time
IMUX's total liabilities is up by 49% year-on-year and by 25% since the previous quarter
The company's debt is 100% lower than its equity
The company's debt to equity has surged by 100% QoQ and by 100% YoY
The company's debt rose by 36% QoQ but it fell by 30% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.